3-HO-PCE

3-HO-PCE: Research Chemical Profile, Structure, and Legal Overview

3-HO-PCE (3-Hydroxyeticyclidine) is a dissociative arylcyclohexylamine, structurally related to PCE (eticyclidine) and 3-HO-PCP. It is used in scientific and analytical research due to its interaction with the NMDA receptor system, which may produce dissociative effects similar to ketamine or PCP analogs.

Although 3-HO-PCE has appeared on the gray market, it is not approved for human consumption or therapeutic use. It is strictly intended for forensic, chemical, and pharmacological research applications.

Chemical Structure and Properties

3-HO-PCE belongs to the broader class of arylcyclohexylamines, known for their potent activity as NMDA receptor antagonists. The compound is distinguished by a hydroxy substitution at the 3-position, which may influence receptor binding dynamics and metabolism.

  • IUPAC Name: 3-[1-(ethylamino)cyclohexyl]phenol

  • Molecular Formula: C14H21NO

  • Chemical Class: Arylcyclohexylamine, dissociative anesthetic

  • Typical Appearance: White crystalline powder or off-white solid

  • Common Usage: In vitro receptor binding and pharmacological modeling studies

Due to its unique hydroxy substitution, 3-HO-PCE is often of interest to researchers exploring SAR (structure-activity relationships) within dissociative compounds.

Reported Effects (Anecdotal)

While there is limited formal data on 3-HO-PCE’s pharmacology, anecdotal accounts suggest its effects may lie between those of 3-MeO-PCE and ketamine, possibly with a longer duration and more pronounced dissociation.

Reported effects (unverified) include:

  • Dissociative or dream-like states

  • Altered sense of body and time

  • Analgesia or reduced physical sensation

  • Decreased motor coordination

  • Mental detachment or introspection

These effects are speculative and not backed by controlled clinical trials. All testing should remain in vitro or in vivo under controlled scientific conditions.

Safety, Toxicology, and Handling

As with other arylcyclohexylamines, the long-term safety profile of 3-HO-PCE is not established. Researchers should handle the compound with extreme care, following all lab safety protocols.

Potential risks may include:

  • Cognitive suppression

  • Elevated blood pressure and heart rate

  • Disorientation or confusion

  • Respiratory or neurological side effects at high concentrations

  • Unknown drug-drug interactions or cumulative toxicity

Use of personal protective equipment (PPE), proper containment systems, and certified laboratory handling procedures is essential.

Legal Status of 3-HO-PCE

The legal status of 3-HO-PCE varies by country and is evolving as authorities respond to emerging psychoactive substances.

  • United States: Not federally scheduled, but may be prosecutable under the Federal Analog Act

  • United Kingdom: Potentially restricted under the Psychoactive Substances Act (PSA)

  • Germany: Controlled under the NpSG (New Psychoactive Substances Act)

  • Canada & Australia: May fall under analog substance laws

  • European Union: Individual member states may regulate it under local NPS legislation

Before purchase or handling, researchers must ensure compliance with local, national, and international laws.

For Research Use Only

3-HO-PCE is not intended for human or veterinary use. It is supplied exclusively for analytical, forensic, and academic research by professionals in certified laboratory environments.

Possession or use outside these contexts may be unlawful and dangerous. All research activities must adhere to relevant safety, legal, and ethical guidelines.

Shopping Cart